Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern Brazil
Carbapenem-resistant Enterobacterales (CRE) are a subject of global concern as limited therapeutic options are available. New combinations of β-lactams and β-lactamase inhibitors, such as ceftazidime-avibactam (CAZ-AVI), have recently been approved in Brazil for the treatment of CRE infections. Cas...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hospital de Clinicas de Porto Alegre ; Universidade Federal do Rio Grande do Sul (UFRGS)
2023-11-01
|
| Series: | Clinical and Biomedical Research |
| Subjects: | |
| Online Access: | https://seer.ufrgs.br/index.php/hcpa/article/view/128523 |
| _version_ | 1797447482972569600 |
|---|---|
| author | Natália Kehl Moreira Gabriela da Silva Collar Priscila Lamb Wink Afonso Luís Barth Juliana Caierão |
| author_facet | Natália Kehl Moreira Gabriela da Silva Collar Priscila Lamb Wink Afonso Luís Barth Juliana Caierão |
| author_sort | Natália Kehl Moreira |
| collection | DOAJ |
| description |
Carbapenem-resistant Enterobacterales (CRE) are a subject of global concern as limited therapeutic options are available. New combinations of β-lactams and β-lactamase inhibitors, such as ceftazidime-avibactam (CAZ-AVI), have recently been approved in Brazil for the treatment of CRE infections. Cases of resistance during treatment or even without previous CAZ-AVI use have been published and it is worrisome in scenarios where KPC-producing Gram-negative bacilli are endemic, as in Brazil. We aimed to assess CAZ-AVI susceptibility among a CRE population recovered from hospitalized patients in Southern Brazil from 2015 to 2021. CAZ-AVI minimal inhibitory concentration (MIC) was determined by antibiotic gradient strips. All the 238 evaluated KPC-producing Enterobacterales were susceptible to CAZ-AVI (MIC = 0.25 to 8 µg/mL), with seven isolates presenting borderline MICs (8 µg/mL). Considering the clinical importance of this new antibiotic in Brazil, we emphasize the importance of surveillance studies to eventually detect resistance phenotypes or even increasing CAZ-AVI MICs.
|
| first_indexed | 2024-03-09T13:56:39Z |
| format | Article |
| id | doaj.art-fc68fc5fb78e4c69b7ee451632574249 |
| institution | Directory Open Access Journal |
| issn | 2357-9730 |
| language | English |
| last_indexed | 2024-03-09T13:56:39Z |
| publishDate | 2023-11-01 |
| publisher | Hospital de Clinicas de Porto Alegre ; Universidade Federal do Rio Grande do Sul (UFRGS) |
| record_format | Article |
| series | Clinical and Biomedical Research |
| spelling | doaj.art-fc68fc5fb78e4c69b7ee4516325742492023-11-30T18:13:00ZengHospital de Clinicas de Porto Alegre ; Universidade Federal do Rio Grande do Sul (UFRGS)Clinical and Biomedical Research2357-97302023-11-01433Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern BrazilNatália Kehl Moreira0Gabriela da Silva CollarPriscila Lamb WinkAfonso Luís BarthJuliana CaierãoUniversidade Federal do Rio Grande do Sul Carbapenem-resistant Enterobacterales (CRE) are a subject of global concern as limited therapeutic options are available. New combinations of β-lactams and β-lactamase inhibitors, such as ceftazidime-avibactam (CAZ-AVI), have recently been approved in Brazil for the treatment of CRE infections. Cases of resistance during treatment or even without previous CAZ-AVI use have been published and it is worrisome in scenarios where KPC-producing Gram-negative bacilli are endemic, as in Brazil. We aimed to assess CAZ-AVI susceptibility among a CRE population recovered from hospitalized patients in Southern Brazil from 2015 to 2021. CAZ-AVI minimal inhibitory concentration (MIC) was determined by antibiotic gradient strips. All the 238 evaluated KPC-producing Enterobacterales were susceptible to CAZ-AVI (MIC = 0.25 to 8 µg/mL), with seven isolates presenting borderline MICs (8 µg/mL). Considering the clinical importance of this new antibiotic in Brazil, we emphasize the importance of surveillance studies to eventually detect resistance phenotypes or even increasing CAZ-AVI MICs. https://seer.ufrgs.br/index.php/hcpa/article/view/128523Ceftazidime-avibactamEnterobacteralesCarbapenemaseResistance |
| spellingShingle | Natália Kehl Moreira Gabriela da Silva Collar Priscila Lamb Wink Afonso Luís Barth Juliana Caierão Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern Brazil Clinical and Biomedical Research Ceftazidime-avibactam Enterobacterales Carbapenemase Resistance |
| title | Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern Brazil |
| title_full | Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern Brazil |
| title_fullStr | Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern Brazil |
| title_full_unstemmed | Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern Brazil |
| title_short | Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern Brazil |
| title_sort | ceftazidime avibactam susceptibility among kpc producing enterobacterales in southern brazil |
| topic | Ceftazidime-avibactam Enterobacterales Carbapenemase Resistance |
| url | https://seer.ufrgs.br/index.php/hcpa/article/view/128523 |
| work_keys_str_mv | AT nataliakehlmoreira ceftazidimeavibactamsusceptibilityamongkpcproducingenterobacteralesinsouthernbrazil AT gabrieladasilvacollar ceftazidimeavibactamsusceptibilityamongkpcproducingenterobacteralesinsouthernbrazil AT priscilalambwink ceftazidimeavibactamsusceptibilityamongkpcproducingenterobacteralesinsouthernbrazil AT afonsoluisbarth ceftazidimeavibactamsusceptibilityamongkpcproducingenterobacteralesinsouthernbrazil AT julianacaierao ceftazidimeavibactamsusceptibilityamongkpcproducingenterobacteralesinsouthernbrazil |